ASTH PE Ratio & Valuation,Is ASTH Overvalued

ASTH Relative Valuation

ASTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASTH is overvalued; if below, it's undervalued.

Historical Valuation

Astrana Health Inc (ASTH) is now in the Fair zone, suggesting that its current forward PE ratio of 30.44 is considered Fairly compared with the five-year average of 37.31. The fair price of Astrana Health Inc (ASTH) is between 17.86 to 46.43 according to relative valuation methord.

Relative Value

Fair Zone

17.86-46.43

Current Price：28.22

Fair

30.44

6.49

EV/EBITDA

Astrana Health Inc. (ASTH) has a current EV/EBITDA of 6.49. The 5-year average EV/EBITDA is 11.56. The thresholds are as follows: Strongly Undervalued below -1.25, Undervalued between -1.25 and 5.15, Fairly Valued between 17.97 and 5.15, Overvalued between 17.97 and 24.38, and Strongly Overvalued above 24.38. The current Forward EV/EBITDA of 6.49 falls within the Historic Trend Line -Fairly Valued range.

12.90

EV/EBIT

Astrana Health Inc. (ASTH) has a current EV/EBIT of 12.90. The 5-year average EV/EBIT is 18.11. The thresholds are as follows: Strongly Undervalued below -1.82, Undervalued between -1.82 and 8.14, Fairly Valued between 28.07 and 8.14, Overvalued between 28.07 and 38.03, and Strongly Overvalued above 38.03. The current Forward EV/EBIT of 12.90 falls within the Historic Trend Line -Fairly Valued range.

0.33

Astrana Health Inc. (ASTH) has a current PS of 0.33. The 5-year average PS is 1.34. The thresholds are as follows: Strongly Undervalued below -0.78, Undervalued between -0.78 and 0.28, Fairly Valued between 2.39 and 0.28, Overvalued between 2.39 and 3.45, and Strongly Overvalued above 3.45. The current Forward PS of 0.33 falls within the Historic Trend Line -Fairly Valued range.

14.87

P/OCF

Astrana Health Inc. (ASTH) has a current P/OCF of 14.87. The 5-year average P/OCF is 16.55. The thresholds are as follows: Strongly Undervalued below -7.09, Undervalued between -7.09 and 4.73, Fairly Valued between 28.37 and 4.73, Overvalued between 28.37 and 40.20, and Strongly Overvalued above 40.20. The current Forward P/OCF of 14.87 falls within the Historic Trend Line -Fairly Valued range.

16.46

P/FCF

Astrana Health Inc. (ASTH) has a current P/FCF of 16.46. The 5-year average P/FCF is 20.56. The thresholds are as follows: Strongly Undervalued below -8.84, Undervalued between -8.84 and 5.86, Fairly Valued between 35.27 and 5.86, Overvalued between 35.27 and 49.97, and Strongly Overvalued above 49.97. The current Forward P/FCF of 16.46 falls within the Historic Trend Line -Fairly Valued range.

Astrana Health Inc (ASTH) has a current Price-to-Book (P/B) ratio of 1.61. Compared to its 3-year average P/B ratio of 2.63 , the current P/B ratio is approximately -38.94% higher. Relative to its 5-year average P/B ratio of 3.65, the current P/B ratio is about -56.03% higher. Astrana Health Inc (ASTH) has a Forward Free Cash Flow (FCF) yield of approximately 7.67%. Compared to its 3-year average FCF yield of 4.19%, the current FCF yield is approximately 82.76% lower. Relative to its 5-year average FCF yield of 3.35% , the current FCF yield is about 129.01% lower.

1.61

P/B

Median3y

2.63

Median5y

3.65

7.67

FCF Yield

Median3y

4.19

Median5y

3.35

Competitors Valuation Multiple

The average P/S ratio for ASTH's competitors is 1.43, providing a benchmark for relative valuation. Astrana Health Inc Corp (ASTH) exhibits a P/S ratio of 0.33, which is -76.91% above the industry average. Given its robust revenue growth of 99.71%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ASTH decreased by 23.57% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 478.71M to 956.05M.

The secondary factor is the P/E Change, contributed -26.05%to the performance.

Overall, the performance of ASTH in the past 1 year is driven by Revenue Growth. Which is more sustainable.

99.71%

478.71M → 956.05M

Revenue Growth

-97.23%

3.97 → 0.11

Margin Expansion

-26.05%

174.56 → 129.09

P/E Change

-23.57%

36.87 → 28.18

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Astrana Health Inc (ASTH) currently overvalued or undervalued?

What is Astrana Health Inc (ASTH) fair value?

ASTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Astrana Health Inc (ASTH) is between 17.86 to 46.43 according to relative valuation methord.

How does ASTH's valuation metrics compare to the industry average?

What is the current P/B ratio for Astrana Health Inc (ASTH) as of Jan 08 2026?

As of Jan 08 2026, Astrana Health Inc (ASTH) has a P/B ratio of 1.61. This indicates that the market values ASTH at 1.61 times its book value.

What is the current FCF Yield for Astrana Health Inc (ASTH) as of Jan 08 2026?

As of Jan 08 2026, Astrana Health Inc (ASTH) has a FCF Yield of 7.67%. This means that for every dollar of Astrana Health Inc’s market capitalization, the company generates 7.67 cents in free cash flow.

What is the current Forward P/E ratio for Astrana Health Inc (ASTH) as of Jan 08 2026?

As of Jan 08 2026, Astrana Health Inc (ASTH) has a Forward P/E ratio of 30.44. This means the market is willing to pay $30.44 for every dollar of Astrana Health Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Astrana Health Inc (ASTH) as of Jan 08 2026?

As of Jan 08 2026, Astrana Health Inc (ASTH) has a Forward P/S ratio of 0.33. This means the market is valuing ASTH at $0.33 for every dollar of expected revenue over the next 12 months.

ASTH Valuation